UNSTOPPABLE,
TOGETHER

BEXLUTRY helps bring your path into focus—combining effective treatment with dedicated support so you can move forward with clarity and confidence in your GEP-NET journey

What is BEXLUTRY?

BEXLUTRY (lutetium Lu 177 dotatate injection) is a radioligand therapy (RLT), also known as peptide receptor radionuclide therapy (PRRT), that works by targeting somatostatin receptor–positive (SSTR+) GEP-NET cells (the abnormal cells) and damages them with radiation.

What to expect from treatment with BEXLUTRY

Starting a new treatment can feel easier when you know what to expect. From your first appointment through follow-up, your care team can help you know what to expect before, during, and after your BEXLUTRY infusions.

Dedicated support every step of the way*

With BEXLUTRY, you have access to ongoing educational, financial, and other support to help you navigate treatment.

*Enrollment in Curium Connects is required to determine eligibility and participation. Offers subject to a maximum benefit per course of treatment.

BEXLUTRY is backed by Curium’s commitment to the neuroendocrine tumor (NET) community

BEXLUTRY was developed by Curium, a US-based radiopharmaceutical company dedicated to supporting people living with NETs. Since 1994, Curium has focused on advancing diagnosis and treatment options for the NET community.

Learn about an imaging tool that can help diagnose GEP-NETs